11:02 AM
 | 
Jun 13, 2018
 |  BC Extra  |  Company News

FDA wants more info on scPharmaceuticals’ Furoscix

scPharmaceuticals Inc. (NASDAQ:SCPH) dropped $1.68 (22%) to $5.93 Wednesday after it received a complete response letter from FDA for an NDA for Furoscix (scFurosemide) to treat edema in patients...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >